The goal of the NCI National Clinical Trials Network (NCTN) is to develop and conduct state-of-the-art cancer treatment and advanced imaging clinical trials, especially large, definitive multi-institutional trials evaluating new cancer therpies and related clinical approaches. NCTN Lead Academic Participating Sites (LAPS) are one component of this network and will provide scientific leadership in the development and conduct of NCTN clinical trials in association with one or more adult Network Groups as well as substantial accrual to clinical trials conducted across the entire NTCN. The Fred Hutchinson Cancer Research Center (FHCRC) is among the nation's leading cancer centers and is the only NCI-designated comprehensive cancer research center serving the WWAMI (Washington, Wyoming, Alaska, Montana and Idaho) region. The broad and deep pre-clinical and clinical research programs at the FHCRC will support the NCTN Program in three major ways: (1) The scientific expertise of the members of the FHCRC will continue to contribute to the leadership of the NCTN program through their activities directly at the NCI and in SWOG, NRG and ACRIN. (2) The innovative pre-clinical and clinical research studies at the FHCRC will provide the preliminary information necessary to shape the next generation of cooperative group trials. (3) The large patient base at the FHCRC combined with expert clinicians and clinical trials infrastructure will assure substantial accrual to NCTN trials. Fred Hutchinson Cancer Research Center and its partners are committed to the goals of the National Clinical Trials Network (NCTN) and will work to provide leadership for our nation's clinical trials network.

Public Health Relevance

In 2012, approximately 1.64 million individuals in the United States will be diagnosed with cancer and 577,000 will die of the disease. Clearly, new approaches to cancer prevention, diagnosis, and treatment are needed and these will only come from new insights achieved through research. As one of the leading cancer research centers in the country, the Fred Hutchinson Cancer Research Center can help provide leadership for our nation's clinical trials network.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
1U10CA180828-01
Application #
8605625
Study Section
Special Emphasis Panel (ZCA1-GRB-P (O1))
Program Officer
Mooney, Margaret M
Project Start
2014-05-20
Project End
2019-02-28
Budget Start
2014-05-20
Budget End
2015-02-28
Support Year
1
Fiscal Year
2014
Total Cost
$1,462,985
Indirect Cost
$511,431
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Meropol, Neal J; Feng, Yang; Grem, Jean L et al. (2018) Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ECOG-ACRIN Cancer Research Group (E4203). Cancer 124:688-697
Byrd, John C; Ruppert, Amy S; Heerema, Nyla A et al. (2018) Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Adv 2:1705-1718
Hussain, Maha; Tangen, Catherine M; Thompson Jr, Ian M et al. (2018) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol 36:1498-1504
Rakovitch, E; Gray, R; Baehner, F L et al. (2018) Refined estimates of local recurrence risks by DCIS score adjusting for clinicopathological features: a combined analysis of ECOG-ACRIN E5194 and Ontario DCIS cohort studies. Breast Cancer Res Treat 169:359-369
Cheng, Heather H; Plets, Melissa; Li, Hongli et al. (2018) Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. Prostate 78:121-127
Lemieux, Julie; Brundage, Michael D; Parulekar, Wendy R et al. (2018) Quality of Life From Canadian Cancer Trials Group MA.17R: A Randomized Trial of Extending Adjuvant Letrozole to 10 Years. J Clin Oncol 36:563-571
Rimsza, Lisa M; Li, Hongli; Braziel, Rita M et al. (2018) Impact of histological grading on survival in the SWOG S0016 follicular lymphoma cohort. Haematologica 103:e151-e153
Mongiovi, Jennifer M; Zirpoli, Gary R; Cannioto, Rikki et al. (2018) Associations between self-reported diet during treatment and chemotherapy-induced peripheral neuropathy in a cooperative group trial (S0221). Breast Cancer Res 20:146
Halpern, Anna B; Othus, Megan; Huebner, Emily M et al. (2018) Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms. Leukemia :
Ignatz-Hoover, James J; Wang, Victoria; Mackowski, Nathan M et al. (2018) Aberrant GSK3? nuclear localization promotes AML growth and drug resistance. Blood Adv 2:2890-2903

Showing the most recent 10 out of 39 publications